Phil Nadeau

The performance of the tardive dyskinesia drug Ingrezza had sell-side analysts gushing over Neurocrine Biosciences, Inc. (NASDAQ: NBIX)'s third-quarter results. Given the buoyancy surrounding Ingrezza, analysts scrambled to designate Neurocrine as their top mid-cap pick. Ingrezza...

Genocea Biosciences Inc GNCA) announced late Monday that it is effecting a strategic shift to immuno-oncology. The company also said it would focus on the development of neoantigen cancer vaccines, including GEN-009, and that it would explore strategic alternatives for GEN-003. Reacting to the...

The big news for the week in the biotech space is the huge $12 billion buyout of Kite Pharma Inc (NASDAQ: KITE) by Gilead Sciences, Inc. (NASDAQ: GILD). Gilead, Kite and other biotech investors are eager to know Wall Street’s take on the big deal and what it means for the market. Related Link...

Following strong Phase I and II data on Tuesday from three different triple combo regimens for cystic fibrosis, shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) rocketed 30 percent Wednesday to $162.07. The stock’s climb to a new all-time high was assisted by a string of analyst...

Encouraging early results from a trial of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) dwarfism treatment sent the company's shares higher Thursday while analysts boosted their targets. Shares changed hands recently at $138.50, up 12 percent. BioMarin said a trial of its vosoritide drug in...

The American Association of Neurology is hosting its annual meeting this week in Washington, DC. Through the end of this week, major biotechnology companies will be making presentations highlighting drug breakthroughs and updates. Analysts at Cowen & Co., led by Ritu Baral, highlighted what...